|
|
|
| Study on the Clinical Efficacy and Safety of Pirarubicin, Gemcitabine and Cisplatin in the Treatment of Advanced Bladder Cancer |
| HUANG Yin-qing, LIU Ling, LIU Shuang, et al |
| Department of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China |
|
|
|
|
Abstract 【Objective】 To analyze the clinical efficacy and safety of pirarubicin, gemcitabine and cisplatin in the treatment of advanced bladder cancer. 【Methods】 A total of 575 patients with advanced bladder cancer were randomly divided into the control group (286 cases) and the research group (289 cases). Patients in the control group received gemcitabine and cisplatin treatment, while patients in the research group received pirarubicin in addition to gemcitabine and ciaplatin. The clinical efficacy, tumor markers, safety and survival of the two groups were compared. 【Results】 The total effective rate in the research group was 77.51% (224/289), which was significantly higher than that of the control group (51.75%, 148/286). The difference was statistically significant (P<0.05). Serum fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and secretory protein (DKK) levels decreased in both groups compared with before treatment, Levels in the research group were significantly lower than those in the control group(P<0.05). There was no significant difference in the incidence of nausea and vomiting, neutropenia, and rash between the two groups(P>0.05). The incidence of thrombocytopenia, alopecia, and fatigue in the research group was higher than that in the control group. The difference was statistically significant between the two groups (P<0.05). The 1-year and 2-year overall survival rates of the resaerch group were 83.74%(242/289)and 61.25%(177/289), respectively, which were higher than the control group's 61.19%(175/286)and 35.31%(101/286), respectively (P<0.05). 【Conclusion】 Clinical efficacy of pirarubicin, gemcitabine combined with cisplatin in the treatment of advanced bladder cancer is superior to gemcitabine plus cisplatin, which can improve the patients' survival time without significantly increasing the adverse reactions.
|
|
Received: 17 March 2018
|
|
|
|
|
|
[1] 刘亦赤. 联合检测尿液NMP22与HA在膀胱癌诊断中的应用[J].医学临床研究, 2016, 33(8):1550-1554.
[2] 赵建华, 王晨宇, 罗勇,等. 吉西他滨+顺铂联合化疗在保留膀胱治疗肌层浸润性膀胱癌的临床疗效评价[J].国际泌尿系统杂志, 2016, 36(4):491-494.
[3] 陈金华, 梁昌卫, 梁培育,等. 吡柔比星联合顺铂膀胱灌注化疗对早期膀胱癌VEGF和HER-2表达的影响[J].河北医药, 2017, 39(6):840-843.
[4] 符伟军. 膀胱癌患者诊疗指南[M].北京:人民军医出版社,2014:214-220.
[5] 柳影, 程颖. 实体肿瘤疗效评价标准的研究[J].实用肿瘤学杂志, 2004, 18(2):149-152.
[6] Kashiwagi E, Ide H, Inoue S,et al.Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer[J].Oncotarget,2016, 7(31):49169-49179.
[7] 任庆,熊锐华,田秀荣,等. 吉西他滨联合顺铂治疗晚期膀胱癌的临床观察[J].重庆医学,2014,43(34):4660-4661.
[8] 许涛, 李际桐, 杨德君,等. 吉西他滨膀胱灌注化疗的临床研究[J].实用药物与临床, 2016, 19(8):949-951.
[9] 罗松涛, 王应洪, 廖大忠,等. 吡柔比星热灌注联合全身化疗治疗晚期膀胱癌的疗效与安全性评价[J].中国临床药理学杂志, 2015,31(3):184-186.
[10] 卢炳新, 孙二琳, 王丽宁. MCP-1与VEGF在膀胱癌组织中的表达及作用机制[J].中国老年学, 2016, 36(23):5891-5893. |
|
|
|
2019, Vol. 36 
